Literature DB >> 18922916

Cell motility in chronic lymphocytic leukemia: defective Rap1 and alphaLbeta2 activation by chemokine.

Kathleen J Till1, Robert J Harris, Andrea Linford, David G Spiller, Mirko Zuzel, John C Cawley.   

Abstract

Chemokine-induced activation of alpha4beta1 and alphaLbeta2 integrins (by conformational change and clustering) is required for lymphocyte transendothelial migration (TEM) and entry into lymph nodes. We have previously reported that chemokine-induced TEM is defective in chronic lymphocytic leukemia (CLL) and that this defect is a result of failure of the chemokine to induce polar clustering of alphaLbeta2; engagement of alpha4beta1 and autocrine vascular endothelial growth factor (VEGF) restore clustering and TEM. The aim of the present study was to characterize the nature of this defect in alphaLbeta2 activation and determine how it is corrected. We show here that the alphaLbeta2 of CLL cells is already in variably activated conformations, which are not further altered by chemokine treatment. Importantly, such treatment usually does not cause an increase in the GTP-loading of Rap1, a GTPase central to chemokine-induced activation of integrins. Furthermore, we show that this defect in Rap1 GTP-loading is at the level of the GTPase and is corrected in CLL cells cultured in the absence of exogenous stimuli, suggesting that the defect is the result of in vivo stimulation. Finally, we show that, because Rap1-induced activation of both alpha4beta1 and alphaLbeta2 is defective, autocrine VEGF and chemokine are necessary to activate alpha4beta1 for ligand binding. Subsequently, this binding and both VEGF and chemokine stimulation are all needed for alphaLbeta2 activation for motility and TEM. The present study not only clarifies the nature of the alphaLbeta2 defect of CLL cells but is the first to implicate activation of Rap1 in the pathophysiology of CLL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922916     DOI: 10.1158/0008-5472.CAN-08-1758

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Authors:  M Martínez-Moreno; M Leiva; N Aguilera-Montilla; S Sevilla-Movilla; S Isern de Val; N Arellano-Sánchez; N C Gutiérrez; R Maldonado; J Martínez-López; I Buño; J A García-Marco; P Sánchez-Mateos; A Hidalgo; A García-Pardo; J Teixidó
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

2.  RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

Authors:  Anja Troeger; Amy J Johnson; Jenna Wood; William G Blum; Leslie A Andritsos; John C Byrd; David A Williams
Journal:  Blood       Date:  2012-04-03       Impact factor: 22.113

3.  G protein betagamma subunits regulate cell adhesion through Rap1a and its effector Radil.

Authors:  Syed M Ahmed; Avais M Daulat; Alexandre Meunier; Stephane Angers
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

4.  Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

Authors:  John C Riches; Conor J O'Donovan; Sarah J Kingdon; Fabienne McClanahan; Andrew J Clear; Donna S Neuberg; Lillian Werner; Carlo M Croce; Alan G Ramsay; Laura Z Rassenti; Thomas J Kipps; John G Gribben
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

5.  Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

Authors:  Kathleen J Till; Andrew R Pettitt; Joseph R Slupsky
Journal:  J Immunol       Date:  2015-01-28       Impact factor: 5.422

6.  Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Authors:  Gina L Eagle; Jianguo Zhuang; Rosalind E Jenkins; Kathleen J Till; Puthen V Jithesh; Ke Lin; Gillian G Johnson; Melanie Oates; Kevin Park; Neil R Kitteringham; Andrew R Pettitt
Journal:  Mol Cell Proteomics       Date:  2015-02-02       Impact factor: 5.911

Review 7.  Role of LFA-1 and ICAM-1 in Cancer.

Authors:  Manuel Reina; Enric Espel
Journal:  Cancers (Basel)       Date:  2017-11-03       Impact factor: 6.639

8.  Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia.

Authors:  Di Huang; Ivan Ovcharenko
Journal:  BMC Genomics       Date:  2017-03-16       Impact factor: 3.969

Review 9.  The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Authors:  Graham Packham; Serge Krysov; Alex Allen; Natalia Savelyeva; Andrew J Steele; Francesco Forconi; Freda K Stevenson
Journal:  Haematologica       Date:  2014-07       Impact factor: 9.941

10.  EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasation.

Authors:  Miguel A Flores; Paula Fortea; Eva M Trinidad; Dolores García; Gloria Soler; Francisco J Ortuño; Agustín G Zapata; Luis M Alonso-Colmenar
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.